Published in Cancer on December 01, 2007
MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer (2010) 1.48
Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer (2009) 1.28
Recent advances in the surgical treatment of hepatocellular carcinoma. World J Gastroenterol (2014) 1.06
Hepatocellular carcinoma: current management and future development-improved outcomes with surgical resection. Int J Hepatol (2011) 1.06
Therapeutic efficacy and fate of bimodal engineered stem cells in malignant brain tumors. Stem Cells (2013) 1.03
Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus. Surg Today (2013) 1.01
Clinical significance of surgical resection of metastatic lymph nodes from hepatocellular carcinoma. Surg Today (2014) 0.94
Insulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells. Br J Cancer (2010) 0.90
Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein. World J Hepatol (2015) 0.89
Statin-Based Palliative Therapy for Hepatocellular Carcinoma. Medicine (Baltimore) (2015) 0.88
Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells. BMC Cancer (2009) 0.87
Autologous formalin-fixed tumor vaccine suppressed re-recurrence of HCV-related hepatocellular carcinoma following 29 unsuccessful treatments with extensive conventional therapy: a case report. World J Surg Oncol (2012) 0.85
Long-term interferon-α treatment suppresses tumor growth but promotes metastasis capacity in hepatocellular carcinoma. J Cancer Res Clin Oncol (2010) 0.85
Interferon-α acts on the S/G2/M phases to induce apoptosis in the G1 phase of an IFNAR2-expressing hepatocellular carcinoma cell line. J Biol Chem (2014) 0.83
Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? World J Gastroenterol (2012) 0.82
Herbal compound "Songyou Yin" reinforced the ability of interferon-alfa to inhibit the enhanced metastatic potential induced by palliative resection of hepatocellular carcinoma in nude mice. BMC Cancer (2010) 0.82
Direct transformation of lung microenvironment by interferon-α treatment counteracts growth of lung metastasis of hepatocellular carcinoma. PLoS One (2013) 0.82
Hepatocellular carcinoma, with portal thrombus after viral eradication, disappeared by 5-fluorouracil and interferon. World J Hepatol (2010) 0.82
Combined IFN-α and 5-FU treatment as a postoperative adjuvant following surgery for hepatocellular carcinoma with portal venous tumor thrombus. Exp Ther Med (2012) 0.81
Accomplishments in 2007 in the management of hepatobiliary cancers. Gastrointest Cancer Res (2008) 0.81
Recent advances in liver resection for hepatocellular carcinoma. Front Surg (2014) 0.81
Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. J Gastroenterol (2012) 0.81
Pegylated interferon-α2a inhibits proliferation of human liver cancer cells in vitro and in vivo. PLoS One (2013) 0.80
Interferon-alpha restrains growth and invasive potential of hepatocellular carcinoma induced by hepatitis B virus X protein. World J Gastroenterol (2008) 0.77
Viral hepatitis and hepatocellular carcinoma: etiology and management. J Gastrointest Oncol (2017) 0.77
Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method. Cancer Med (2015) 0.76
Combination therapy with S-1 and interferon-α in hepatocellular carcinoma patients with lung metastasis. Mol Clin Oncol (2014) 0.75
Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence. Oncol Lett (2016) 0.75
Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. J Biol Chem (2003) 3.41
A Bayesian missing value estimation method for gene expression profile data. Bioinformatics (2003) 3.19
Genome-wide expression analysis of mouse liver reveals CLOCK-regulated circadian output genes. J Biol Chem (2003) 2.66
Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol (2008) 2.64
Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res (2007) 2.29
Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res (2007) 2.19
Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol (2011) 2.18
Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg (2013) 2.17
A prospective trial for avoiding cervical lymph node dissection for thoracic esophageal cancers, based on intra-operative genetic diagnosis of micrometastasis in recurrent laryngeal nerve chain nodes. J Surg Oncol (2006) 2.16
Subcuticular sutures versus staples for skin closure after open gastrointestinal surgery: a phase 3, multicentre, open-label, randomised controlled trial. Lancet (2013) 2.14
Operative morbidity of living liver donors in Japan. Lancet (2003) 2.13
Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol (2004) 2.10
High incidence of thrombosis of the portal venous system after laparoscopic splenectomy: a prospective study with contrast-enhanced CT scan. Ann Surg (2005) 2.04
Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery (2008) 2.04
Adaptive servo-ventilation therapy for patients with chronic heart failure in a confirmatory, multicenter, randomized, controlled study. Circ J (2015) 2.03
Cardiac side population cells have a potential to migrate and differentiate into cardiomyocytes in vitro and in vivo. J Cell Biol (2007) 2.02
Laparoscopy-assisted hybrid left-side donor hepatectomy. World J Surg (2013) 2.02
Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci (2012) 1.98
Implications of nectin-like molecule-2/IGSF4/RA175/SgIGSF/TSLC1/SynCAM1 in cell-cell adhesion and transmembrane protein localization in epithelial cells. J Biol Chem (2003) 1.86
Biology of hepatocellular carcinoma. Ann Surg Oncol (2008) 1.78
Increased expression of valosin-containing protein (p97) is associated with lymph node metastasis and prognosis of pancreatic ductal adenocarcinoma. Ann Surg Oncol (2004) 1.78
Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer (2007) 1.77
Modeling of the human middle ear using the finite-element method. J Acoust Soc Am (2002) 1.76
Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res (2004) 1.75
Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery (2007) 1.75
Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: implication of tumor vascularization. Clin Cancer Res (2006) 1.75
Outcomes after living donor liver transplantation for acute liver failure in Japan: results of a nationwide survey. Liver Transpl (2012) 1.64
LC3, an autophagosome marker, is highly expressed in gastrointestinal cancers. Int J Oncol (2008) 1.61
Direct binding of cell polarity protein PAR-3 to cell-cell adhesion molecule nectin at neuroepithelial cells of developing mouse. J Biol Chem (2003) 1.60
Donor complications associated with living donor liver transplantation in Japan. Transplantation (2009) 1.60
Diameter of splenic vein is a risk factor for portal or splenic vein thrombosis after laparoscopic splenectomy. Surgery (2009) 1.60
Expression profiles of 39 HOX genes in normal human adult organs and anaplastic thyroid cancer cell lines by quantitative real-time RT-PCR system. Exp Cell Res (2004) 1.59
Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. Circ J (2013) 1.57
Application of molecular diagnosis for detection of peritoneal micrometastasis and evaluation of preoperative chemotherapy in advanced gastric carcinoma. Ann Surg Oncol (2004) 1.54
Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer (2002) 1.54
Risk factors for alcohol relapse after liver transplantation for alcoholic cirrhosis in Japan. Liver Transpl (2014) 1.52
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res (2007) 1.49
Hyponatremia as a predictor for worsening heart failure in patients receiving cardiac resynchronization therapy. Circ J (2012) 1.45
Low-dose vasopressin infusion therapy for refractory hypotension in ELBW infants. Pediatr Int (2009) 1.45
NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res (2004) 1.44
Vestibular evoked myogenic potentials of undiagnosed dizziness. Auris Nasus Larynx (2007) 1.42
Intragraft transcriptome level of CXCL9 as biomarker of acute cellular rejection after liver transplantation. J Surg Res (2012) 1.39
Successful living related liver transplantation in a case with biliary atresia associated with corrected transposition of the great arteries. Pediatr Transplant (2007) 1.39
Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry. J Clin Oncol (2002) 1.36
Cancer gene expression database (CGED): a database for gene expression profiling with accompanying clinical information of human cancer tissues. Nucleic Acids Res (2005) 1.35
T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun (2007) 1.34
Cancer cells survive with survivin. Cancer Sci (2008) 1.33
Identification of expressed genes linked to malignancy of human colorectal carcinoma by parametric clustering of quantitative expression data. Genome Biol (2003) 1.31
Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int (2006) 1.30
Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol Rep (2006) 1.28
Pulmonary tumor thrombotic microangiopathy: a clinical analysis of 30 autopsy cases. Intern Med (2013) 1.26
Cardiomyocytes fuse with surrounding noncardiomyocytes and reenter the cell cycle. J Cell Biol (2004) 1.26
Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med (2010) 1.26
Thrombendvenectomy for organized portal vein thrombosis at the time of liver transplantation. Ann Surg (2002) 1.24
Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res (2006) 1.23